[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338295-105":59,"doc-detail-338295-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","specc1-as-a-pan-cancer-biomarker-unraveling-its-role-in-drug-sensitivity-and-resistance-mechanisms","SPECC1 as a pan-cancer biomarker - unraveling its role in drug sensitivity and resistance mechanisms","","Bioinformatics analyses were used to investigate SPECC1 across pan-cancer datasets including GTEx, CCLE, cBioportal, TCGA, and UCSC XENA, with comparisons to matched normal tissues. Most cancers showed elevated SPECC1 expression, while hepatocellular carcinoma displayed reduced levels; genetic alterations were observed in endometrial cancer, sarcoma, and esophageal cancer. SPECC1 dysregulation correlated with prognosis in multiple malignancies. Pathway enrichment implicated adhesion and collagen-containing extracellular matrix programs, cytokine-cytokine receptor interaction mediators, and PI3K-AKT signaling. Drug-sensitivity assays indicated higher SPECC1 expression associates with increased sensitivity to agents such as docetaxel and doxorubicin.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/specc1-as-a-pan-cancer-biomarker-unraveling-its-role-in-drug-sensitivity-and-resistance-mechanisms/338295/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/specc1-as-a-pan-cancer-biomarker-unraveling-its-role-in-drug-sensitivity-and-resistance-mechanisms/338295.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What datasets and methods were used to study SPECC1 across cancers?","Question",{"text":112,"@type":113},"The study used bioinformatics approaches analyzing literature-reported data and public resources including GTEx, CCLE, cBioportal, TCGA, and UCSC XENA, with comparisons to matched normal tissues.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does SPECC1 expression vary among different tumor types?",{"text":117,"@type":113},"Most cancers exhibited higher SPECC1 levels than matching normal tissues, with pancreatic adenocarcinoma and breast invasive carcinoma highlighted, while hepatocellular carcinoma showed lower expression.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the relationship between SPECC1 and drug response or prognosis?",{"text":121,"@type":113},"SPECC1 dysregulation correlated with prognosis in several cancers, and drug sensitivity assays suggested SPECC1 high-expressing cell lines were more sensitive to drugs including docetaxel and doxorubicin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338295,1790870099,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Analysis  \nSPECC1 as a pan‑cancer biomarker: unraveling its role in drug sensitivity and resistance mechanisms  \nDongwei Liu1 · Xidi Wang2 · Lingfei Cui2 · Mingxia Zhang2 · Kefeng Lei2 · Nijiati Aierken2  \nReceived: 9 August 2024 / Accepted: 4 October 2024  \n© The Author(s) 2024 OPEN  \nAbstract  \nPrevious studies have shown a relationship between SPECC1 and the prognosis of breast cancer, indicating a potential function for SPECC1 in the initiation and progression of cancer. However, the role played by SPECC1 in other tumors is not yet known. Therefore, we used bioinformatics techniques to conduct a thorough investigation into the possible mechanism of SPECC1 in pan-cancer, analyzing data reported in the literature as well as databases such as GTEx and CCLE, cBioportal, TCGA, and UCSC XENA. Comparing the results with matching normal tissues, the majority of cancers, including pancreatic adenocarcinoma (PAAD) and breast invasive carcinoma (BRCA), exhibited higher levels of SPECC1, while hepatocellular carcinoma (HCC) showed lower expression levels. SPECC1 was also found to be genetically mutated in endometrial cancer, sarcoma, and esophageal cancer. The prognosis of lung adenocarcinoma, kidney papillary cell carcinoma, and breast cancer is highly correlated with dysregulation of SPECC1 expression. This work helps guide clinical therapy by highlighting the sensitivity of tumor-treating medicines and the prognostic importance of SPECC1 in various malignancies. KEGG pathway enrichment analysis revealed focused adhesion, collagen-containing extracellular matrix (collagen), and the primary enrichment domains for SPECC1-related genes. These findings were obtained through gene annotation (GO) examination of SPECC1 expression. Primary mediators of the cytokine-cytokine receptor interaction include PICOC1-associated genes, cell-substrate junction genes, and extracellular matrix containing collagen. PICOC1-associated genes primarily mediate the PI3K-AKT signaling pathway. Drug sensitivity assay showed that SPECC1 highexpressing cell lines were more sensitive to docetaxel, doxorubicin, etc. In conclusion, the current study shows how SPECC1 is expressed in different cancers and how this expression relates to the prognosis of the tumor. It also revealed the mutations and copy number variations of SPECC1 in various tumors and its potential involvement in cellular pathway regulatory networks and cytological processes. This study examines the relationship between immune genes, cellular infiltration, and immunological scores in the tumor microenvironment, which explain the severity of the disease. This study looks at the response of SPEC1 expression to anticancer therapy. Explains the prognostic significance and drug response of SPECC-1 .  \nKeywords PECC1 · Pan-cancer · Prognosis · Bioinformatics analysis  \nDongwei Liu and Xidi Wang contributed equally to this work.  \nSupplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12672-024-](https://doi.org/10.1007/s12672-024-)[ ](https://doi.org/10.1007/s12672-024-)[01426-x](01426-x.)[.](01426-x.)  \n* Kefeng Lei, [leikf@mail.sysu.edu.cn](leikf@mail.sysu.edu.cn); * Nijiati Aierken, [nijtaierk3@mail.sysu.edu.cn](nijtaierk3@mail.sysu.edu.cn); Dongwei Liu, [liudw7@mail.sysu.edu.cn](liudw7@mail.sysu.edu.cn); Xidi Wang,  \n[Wangxidily@gmail.com](Wangxidily@gmail.com); Lingfei Cui, [cuilingfei@sysush.com](cuilingfei@sysush.com); Mingxia Zhang, [zhangmingxia@sysush.com |](zhangmingxia@sysush.com |1Department of General)[1](zhangmingxia@sysush.com |1Department of General)[Department of General](zhangmingxia@sysush.com |1Department of General) Practice,  \nThe seventh Affiliated Hospital of sun yat-sen university, Shenzhen 518107, China. 2Department of Thyroid and Breast surgery, The seventh Affiliated Hospital of sun yat-sen university, Shenzhen 518107, China.  \nDiscover Oncology  \n(2024) 15:552  \n| [https://doi.org/10.1007/s12672-024-01426-x](https://","cbCaiuIkP3IR2Z5L","https://ap.wps.com/l/cbCaiuIkP3IR2Z5L","pdf",2004008,14,"English","# Abstract\n# 1 Introduction\n# 2 Results\n## 2.1 Pan-cancer analysis of SPECC1 expression","[{\"question\":\"What datasets and methods were used to study SPECC1 across cancers?\",\"answer\":\"The study used bioinformatics approaches analyzing literature-reported data and public resources including GTEx, CCLE, cBioportal, TCGA, and UCSC XENA, with comparisons to matched normal tissues.\"},{\"question\":\"How does SPECC1 expression vary among different tumor types?\",\"answer\":\"Most cancers exhibited higher SPECC1 levels than matching normal tissues, with pancreatic adenocarcinoma and breast invasive carcinoma highlighted, while hepatocellular carcinoma showed lower expression.\"},{\"question\":\"What is the relationship between SPECC1 and drug response or prognosis?\",\"answer\":\"SPECC1 dysregulation correlated with prognosis in several cancers, and drug sensitivity assays suggested SPECC1 high-expressing cell lines were more sensitive to drugs including docetaxel and doxorubicin.\"}]","SPECC1 as a pan-cancer biomarker - unraveling its role in drug sensitivity and resistance mechanisms | PDF",1790022949,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afc62e060c50dc382afca75332a6159f.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec0897bbb0405b579938b4d2c84e1628.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/212787c85f7e3a38890f7f4b67c7042c.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cae881535ff0b17cbf7733f76c8ddf19.webp",980,1301]